Table I.
Clinicopathological characteristics of the patients according to brachyury expression in nucleus of primary tumor.
| Parameter | Brachyury-negative (n=40) | Brachyury-positive (n=62) | P-value |
|---|---|---|---|
| Age, yearsa | 0.397 | ||
| ≤45 | 12 (30.0) | 25 (40.3) | |
| >45 | 28 (70.0) | 37 (59.7) | |
| pTa | 1.000 | ||
| 1 | 17 (42.5) | 27 (43.5) | |
| 2–4 | 23 (57.5) | 35 (56.5) | |
| pNa | 0.965 | ||
| 0 | 19 (47.5) | 31 (50.0) | |
| 1–3 | 21 (52.5) | 31 (50.0) | |
| Histological gradea | 0.552 | ||
| 1–2 | 20 (50.0) | 36 (58.1) | |
| 3 | 20 (50.0) | 26 (41.9) | |
| Molecular subtypea | 0.316 | ||
| Non-TNBC | 19 (47.5) | 37 (59.7) | |
| TNBC | 21 (52.5) | 25 (40.3) | |
| Lymphovascular invasiona | 0.908 | ||
| Absent | 20 (50.0) | 33 (53.2) | |
| Present | 20 (50.0) | 29 (46.8) | |
| Microcalcificationa | 0.025 | ||
| Absent | 18 (45.0) | 43 (69.4) | |
| Present | 22 (55.0) | 19 (30.6) | |
| Estrogen receptora | 0.052 | ||
| Negative | 28 (70.0) | 30 (48.4) | |
| Positive | 12 (30.0) | 32 (51.6) | |
| Progesterone receptora | 0.125 | ||
| Negative | 30 (75.0) | 36 (58.1) | |
| Positive | 10 (25.0) | 26 (41.9) | |
| HER2a | 0.494 | ||
| Negative | 32 (80.0) | 54 (87.1) | |
| Positive | 8 (20.0) | 8 (12.9) | |
| Type of surgerya | 1.000 | ||
| Conserving surgery | 5 (12.5) | 7 (11.3) | |
| Total mastectomy | 35 (87.5) | 55 (88.7) | |
| Follow up periods, monthsb | 79.2±35.2 | 82.2±42.8 | 0.712 |
| Radiotherapya | 0.526 | ||
| No | 30 (75.0) | 51 (82.3) | |
| Yes | 10 (25.0) | 11 (17.7) | |
| Chemotherapya | 0.665 | ||
| No | 1 (2.5) | 4 (6.5) | |
| Yes | 39 (97.5) | 58 (93.5) | |
| Cytoplasmic brachyurya | 0.069 | ||
| Low | 23 (57.5) | 23 (37.1) | |
| High | 17 (42.5) | 39 (62.9) |
a
Data are presented as n (%).
b
Data are presented as the mean ± standard deviation. TNBC, triple-negative breast cancer; HER2, human epidermal growth factor receptor 2.